Earlier this year the Therapeutic Goods Administration (TGA) conducted a consultation with interested parties on a proposal to restrict public access to Andrographis paniculata (Andrographis). This was based on the notion that it posed a threat to human health due to a number of reported severe allergic reactions, including a reported anaphylaxis-associated fatality.
